Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Autolus Therapeutics announces participation in upcoming conferences By: Autolus Therapeutics plc via GlobeNewswire November 06, 2023 at 07:00 AM EST LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel: Considerations for an Oncology Company’s Autoimmune Side HustleDate and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Jefferies London Healthcare Conference Fireside ChatDate and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Piper Sandler 35th Annual Healthcare Conference Fireside ChatDate and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/ About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com. Contact: Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Autolus Therapeutics announces participation in upcoming conferences By: Autolus Therapeutics plc via GlobeNewswire November 06, 2023 at 07:00 AM EST LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel: Considerations for an Oncology Company’s Autoimmune Side HustleDate and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Jefferies London Healthcare Conference Fireside ChatDate and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Piper Sandler 35th Annual Healthcare Conference Fireside ChatDate and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/ About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com. Contact: Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com
LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its participation in three upcoming conferences in November. Truist Securities BioPharma Symposium Panel: Considerations for an Oncology Company’s Autoimmune Side HustleDate and time: 9 November 2023, 11:40am ET / 16:40pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Jefferies London Healthcare Conference Fireside ChatDate and time: 16 November 2023, 4:00am ET / 9:00am GMTLocation: London, UKPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Piper Sandler 35th Annual Healthcare Conference Fireside ChatDate and time: 28 November 2023, 11:30am ET/ 16:30pm GMTLocation: New York, USAPresenter: Dr Christian Itin, Chief Executive Officer, Autolus Therapeutics Find out more information about upcoming events and any webcast and replay details at: https://www.autolus.com/investor-relations/events/ About Autolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com. Contact: Julia Wilson+44 (0) 7818 430877j.wilson@autolus.com Susan A. NoonanS.A. Noonan Communications+1-917-513-5303susan@sanoonan.com Lauren WilliamsInvestase+44 23 9438 7760lauren@investase.com